BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37937645)

  • 21. Effects of sirolimus in the treatment of unresectable infantile hemangioma and vascular malformations in children: A single-center experience.
    Cho YJ; Kwon H; Kwon YJ; Kim SC; Kim DY; Namgoong JM
    J Vasc Surg Venous Lymphat Disord; 2021 Nov; 9(6):1488-1494. PubMed ID: 33836285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sirolimus in the Treatment of Vascular Anomalies.
    Triana P; Dore M; Cerezo VN; Cervantes M; Sánchez AV; Ferrero MM; González MD; Lopez-Gutierrez JC
    Eur J Pediatr Surg; 2017 Feb; 27(1):86-90. PubMed ID: 27723921
    [No Abstract]   [Full Text] [Related]  

  • 23. The Use of Sirolimus for Treatment of Orbital Lymphatic Malformations: A Systematic Review.
    Shoji MK; Shishido S; Freitag SK
    Ophthalmic Plast Reconstr Surg; 2020; 36(3):215-221. PubMed ID: 31990892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How we approach the use of sirolimus and new agents: Medical therapy to treat vascular anomalies.
    Shimano KA; Eng W; Adams DM
    Pediatr Blood Cancer; 2022 Aug; 69 Suppl 3():e29603. PubMed ID: 35253343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial.
    Lai ZW; Kelly R; Winans T; Marchena I; Shadakshari A; Yu J; Dawood M; Garcia R; Tily H; Francis L; Faraone SV; Phillips PE; Perl A
    Lancet; 2018 Mar; 391(10126):1186-1196. PubMed ID: 29551338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topical sirolimus solution for lingual microcystic lymphatic malformations in children and adults (TOPGUN): study protocol for a multicenter, randomized, assessor-blinded, controlled, stepped-wedge clinical trial.
    Marchand A; Caille A; Gissot V; Giraudeau B; Lengelle C; Bourgoin H; Largeau B; Leducq S; Maruani A
    Trials; 2022 Jul; 23(1):557. PubMed ID: 35804404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral rapamycin: an alternative in children with complicated vascular abnormalities.
    Gómez Sánchez A; Redondo Sedano JV; Pérez Alonso V; Martí Carrera ME; Baro Fernández M; Palencia Pérez SI; Gallego Herrero MC; Gómez Fraile A; Delgado Muñoz MD
    Cir Pediatr; 2020 Oct; 33(4):183-187. PubMed ID: 33016658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Menstrual disorders associated with sirolimus treatment.
    Triana P; López-Gutierrez JC
    Pediatr Blood Cancer; 2021 Mar; 68(3):e28867. PubMed ID: 33369022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences in Efficacy and Safety of Sirolimus and Sildenafil in Pediatric Lymphatic Malformations.
    Wang J; Zhang X; Sun N; Liu Q; Li Y; Peng Y; Cheng X; Zhang J; Liu Y; Feng G; Liu Z; Ji T; Li X; Liu Y; Wang S; Ni X
    Laryngoscope; 2023 Nov; 133(11):3192-3199. PubMed ID: 36861763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No Association of Sirolimus with Wound Complications in Children With Vascular Anomalies.
    Mehl SC; Whitlock RS; Ortega RM; Creden S; Iacobas I; Maricevich RS; Rosenberg TL; Rialon KL
    J Pediatr Surg; 2023 Aug; 58(8):1555-1559. PubMed ID: 36599792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies.
    Ozeki M; Nozawa A; Yasue S; Endo S; Asada R; Hashimoto H; Fukao T
    Orphanet J Rare Dis; 2019 Jun; 14(1):141. PubMed ID: 31196128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of sirolimus in children with lymphatic malformations of the head and neck.
    Wiegand S; Dietz A; Wichmann G
    Eur Arch Otorhinolaryngol; 2022 Aug; 279(8):3801-3810. PubMed ID: 35526176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies.
    Adams DM; Trenor CC; Hammill AM; Vinks AA; Patel MN; Chaudry G; Wentzel MS; Mobberley-Schuman PS; Campbell LM; Brookbank C; Gupta A; Chute C; Eile J; McKenna J; Merrow AC; Fei L; Hornung L; Seid M; Dasgupta AR; Dickie BH; Elluru RG; Lucky AW; Weiss B; Azizkhan RG
    Pediatrics; 2016 Feb; 137(2):e20153257. PubMed ID: 26783326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and absorption of topical sirolimus for the treatment of vascular anomalies in children: A case series.
    Le Sage S; David M; Dubois J; Powell J; McCuaig CC; Théorêt Y; Kleiber N
    Pediatr Dermatol; 2018 Jul; 35(4):472-477. PubMed ID: 29790593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BMI in childhood and adolescence is associated with impaired reproductive function-a population-based cohort study from birth to age 50 years.
    Laru J; Nedelec R; Koivuaho E; Ojaniemi M; Järvelin MR; Tapanainen JS; Franks S; Tolvanen M; Piltonen TT; Sebert S; Morin-Papunen L
    Hum Reprod; 2021 Oct; 36(11):2948-2961. PubMed ID: 34364312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe adverse events during sirolimus "off-label" therapy for vascular anomalies.
    Rössler J; Baselga E; Davila V; Celis V; Diociaiuti A; El Hachem M; Mestre S; Haeberli D; Prokop A; Hanke C; Loichinger W; Quéré I; Baumgartner I; Niemeyer CM; Kapp FG
    Pediatr Blood Cancer; 2021 Aug; 68(8):e28936. PubMed ID: 33580918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Our experience with sirolimus for the treatment of complicated vascular anomalies].
    Giménez-Aleixandre C; Méndez-Aguirre NA; Martínez-Menchón T; Girón Vallejo Ó; Fernández-Ibieta M; Ferri-Ñíguez B; Villamil V; Sánchez-Sánchez Á; Montoya-Rangel CA; Hernández-Bermejo JP
    Cir Pediatr; 2019 Jan; 32(1):28-33. PubMed ID: 30714698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of sirolimus in the treatment of vascular anomalies: A systematic review.
    Freixo C; Ferreira V; Martins J; Almeida R; Caldeira D; Rosa M; Costa J; Ferreira J
    J Vasc Surg; 2020 Jan; 71(1):318-327. PubMed ID: 31676179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.